{"id":647071,"date":"2023-04-13T19:42:01","date_gmt":"2023-04-13T19:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=647071"},"modified":"2023-04-13T19:42:01","modified_gmt":"2023-04-13T19:42:01","slug":"multiple-sclerosis-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-landscape-treatment-outlook-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-landscape-treatment-outlook-key-companies_647071.html","title":{"rendered":"Multiple Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Landscape, Treatment Outlook, Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Multiple Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Landscape, Treatment Outlook, Key Companies \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Multiple Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Landscape, Treatment Outlook, Key Companies \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Multiple Sclerosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the Multiple Sclerosis (MS) markets are anticipated to change in the coming years owing to the increasing prevalence of the disease, the launch of novel pipeline therapies, and increasing awareness.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;M<strong>ultiple Sclerosis Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Multiple Sclerosis Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Multiple Sclerosis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/a07f79919d1775f019eecf2a9b885bf4.jpg\" alt=\"Multiple Sclerosis Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Multiple Sclerosis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for the <strong>treatment of Multiple Sclerosis<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Multiple Sclerosis market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mechanisms of Action of the Emerging Pipeline Therapies Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dihydroorotate dehydrogenase inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Agammaglobulinaemia tyrosine kinase inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CD40 ligand inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Endothelial PAS domain-containing protein 1 inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">B-cell activating factor inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Toll-like receptor 4 antagonists<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CD4-positive T lymphocyte stimulant<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunologic cytotoxicity<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cell replacements<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulator<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ENO1 protein inhibitor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bacteria replacements<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Multiple Sclerosis Therapeutic Segment @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple Sclerosis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>There are approx. 100+ key companies developing therapies for Multiple sclerosis. Currently, TG Therapeutics is leading the therapeutic market with its Multiple sclerosis drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Leading Companies in the Multiple Sclerosis Therapeutics Market, Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>AB Science, ABION, Alkermes, ANOKION, Antisense Therapeutics, Apimeds Inc., ASLAN Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Autobahn Therapeutics, Bayer HealthCare, Biocad, Biogen, BrainStorm Cell Limited, Bristol-Myers Squibb, CinnaGen, Clene Nanomedicine, CytoDyn, Emerald Health Pharmaceuticals, f5 Therapeutics, Genentech, GeNeuro SA, GlaxoSmithKline, Gossamer Bio, Hanmi Pharmaceutical, HuniLife Biotechnology, Inc., Immune Response BioPharma, Inc., ImStem Biotechnology, Lucid Psycheceuticals, Mapi Pharma, Merck Healthcare KGaA, Merck Serono, Novartis, Pear Therapeutics, Pipeline Therapeutics, RedHill Biopharma, RemeGen Co., Ltd., Sanofi, Sarepta Therapeutics, TG Therapeutics, Inc., Voronoi, ZyVersa Therapeutics, and many others.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple Sclerosis Emerging and Marketed Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ALKS 8700: Alkermes\/Biogen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ANK-700: ANOKION<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Arbaclofen (Arbaclofen ER): Osmotica Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ATA188: Atara Biotherapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BMS-986196: Bristol Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CNM-Au8: Clene Nanomedicine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Evobrutinib\/M2951: Merck Healthcare KGaA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fenebrutinib: Hoffman-La-Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GB7208: Gossamer Bio<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IMCY-0141: ImCyse<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IMS-001: ImStem Biotechnology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IMU-838: Immunic<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NeuroVax: Immune Response BioPharma, Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pear-006: Pear therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RC18: RemeGen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Temelimab: GeNeuro<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tolebrutinib (SAR442168): Sanofi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ublituximab: TG Therapeutics, Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Multiple Sclerosis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Multiple Sclerosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Multiple Sclerosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Multiple Sclerosis Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Multiple Sclerosis Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Multiple Sclerosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Multiple Sclerosis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Multiple Sclerosis Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Multiple Sclerosis Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Multiple Sclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Multiple Sclerosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Multiple Sclerosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/multiple-sclerosis-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/partner-identification-services\">Healthcare Partner Identification Services<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=multiple-sclerosis-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-landscape-treatment-outlook-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=multiple-sclerosis-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-landscape-treatment-outlook-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Multiple Sclerosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/multiple-sclerosis-pipeline-assessment-2023-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-landscape-treatment-outlook-key-companies_647071.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,426,406,404],"tags":[],"class_list":["post-647071","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Financial-Market","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=647071"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647071\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=647071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=647071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=647071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}